Oncotarget

Researcher Mikhail V. Blagosklonny discusses how rapamycin and other rapalogs can delay cancer by targeting pre-cancerous cells and slowing organismal aging. Clinical trials in high-risk populations are warranted to explore their cancer-preventive effects.

New research paper published in Oncotarget discusses phase I trial of riluzole and sorafenib in patients with advanced solid tumors, showing promising antitumor activity. Researchers identified toxicity profile, dose-limiting toxicities, maximum tolerated dose, and pharmacokinetic properties of the combination. Exploration of overexpression of GRM1 in cancer pathogenesis and efficacy of the combination therapy in patients with refractory solid tumors.

Explore the challenges in treating Triple Negative Breast Cancer (TNBC) despite advancements. Emphasize the importance of molecular markers in treatment regimens. Discuss potential therapeutic strategies to enhance TNBC outcomes.

Researcher Hossein Tavana and expert Gary D. Luker discuss Cancer-associated fibroblasts' role in tumor microenvironment, challenges in targeting them for therapies, and the potential of personalized cancer treatments through better understanding of CAFs.

Researchers Kamrul Hasan and Thomas J. Kipps from the University of California discuss the impact of cortactin in cancer progression, focusing on its role in promoting cell migration and metastasis. They explore its interactions with actin-related proteins, signaling pathways, and its association with cancers like CLL and breast cancer.

The podcast discusses the presence of Impact Journals at the AACR Annual Meeting 2023, emphasizing their focus on cancer and aging research. They invite visitors to connect with the team at Booth 2642 during the event.

Researchers discuss targeting pre-leukemic cells to prevent childhood B-ALL, focusing on genetic mutations and environmental triggers. They explore the efficacy of Roxelitinib in reducing B-ALL incidence in mice and propose ongoing research for preventative strategies against childhood leukemia.

Researchers discuss the impact of angulin-1/LSR downregulation on malignancy in lung adenocarcinoma. They explore abnormal claudin-2 expression and the effects of angulin-1/LSR loss on lung adenocarcinoma cell lines. The study also examines therapeutic approaches for lung adenocarcinoma via cell metabolism modulation, highlighting the potential of AG1478 and EW7197 as treatments.

Researchers discuss the effectiveness of Polyisoprenylated Cysteinyl Amide Inhibitors in depleting G-proteins in lung and breast cancer cells. The study shows promising results with significant decreases in levels of key G proteins, offering potential as anti-cancer agents.

Researchers Fang Cheng, Victor Chérouvrier Hansson, Grigorios Georgolopoulos, and Katrin discuss their recent study on Glypican-1 in cancer. They reveal the correlation between GPC-1 expression and poor prognosis in multiple cancer types. Targeting GPC-1 resulted in cancer cell growth inhibition, highlighting its potential in precision cancer treatment.